Bristol-Pfizer's blood thinner Eliquis wins FDA approval

Bristol-Myers Squibb and Pfizer's Eliquis, or apixaban, has been approved by the FDA to reduce the risk of strokes and blood clots for people with atrial fibrillation. The anticoagulant, however, should not be given to patients with artificial heart valves or those with atrial fibrillation due to heart valve problems, the FDA said. Eliquis, which has been approved in Europe, is seen has having the potential to become a blockbuster.

View Full Article in:

New York Times (tiered subscription model), The · USA Today

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY